TP53, MDM2, NQO1, and susceptibility to cervical cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 3, 2010, Pages 755-761

  Hu, Xiaoxia ^a,b   Zhang, Zhengyan ^a   Ma, Duanduan ^a   Huettner, Phyllis C ^a   Massad, L Stewart ^a   Nguyen, Loan ^a   Borecki, Ingrid ^a   Rader, Janet S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b People's Hospital of Guangxi Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; OXIDOREDUCTASE; PROTEIN MDM2; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE QUINONE OXIDOREDUCTASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CODON; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN STABILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS TYPING;

ADULT; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; UTERINE CERVICAL NEOPLASMS;

EID: 77949725819     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0886     Document Type: Article

References (31)

1. Neuman RJ, Huettner PC, Li L, et al. Association between DQB1 and cervical cancer in patients with human papillomavirus and family controls. Obstet Gynecol 2000;95:134-40.
2. Zhang Z, Borecki I, Nguyen L, et al. CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res 2007;67:11202-8.
3. Yu KJ, Rader JS, Borecki I, Zhang Z, Hildesheim A. CD83 polymorphisms and cervical cancer risk. Gynecol Oncol 2009;114:319-22.
4. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
5. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
6. Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci U S A 2002;99:3099-104.
7. Asher G, Lotem J, Sachs L, Kahana C, Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci U S A 2002;99:13125-30.
8. Michael D, Oren M. The p53-2 module and the ubiquitin system. Semin Cancer Biol 2003;13:49-58.
9. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 2007;16:2717-23.
10. Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG. NAD(P)H: quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 2002;4:62-70.
11. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:979-87.
12. Pan SS, Han Y, Farabaugh P, Xia H. Implication of alternative splicing for expression of a variant NAD(P)H:quinone oxidoreductase-1 with a single nucleotide polymorphism at 465C>T. Pharmacogenetics 2002;12:479-88.
13. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990;18:4961.
14. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
15. Li J, Gerhard DS, Zhang Z, et al. Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus. J Clin Microbiol 2003;41:5563-71.
16. Clayton D, Jones H. Transmission/disequilibrium tests for extended marker haplotypes. Am J Hum Genet 1999;65:1161-9.
17. Burger RA, Monk BJ, Kurosaki T, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996;88:1361-8.
18. Wright JD, Li J, Gerhard DS, et al. Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecol Oncol 2005;98:84-91.
19. Koushik A, Platt RW, Franco EL. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 2004;13:11-22.
20. Jee SH, Won SY, Yun JE, Lee JE, Park JS, Ji SS. Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet 2004;85:301-8.
21. Sousa H, Santos AM, Pinto D, Medeiros R. Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A metaanalysis review within European populations. Int J Mol Med 2007;20:731-41.
22. Ojeda JM, Ampuero S, Rojas P, et al. p53 codon 72 polymorphism and risk of cervical cancer. Biol Res 2003;36:279-83.
23. Govan VA, Loubser S, Saleh D, Hoffman M, Williamson AL. No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency. Int J Immunogenet 2007;34:213-7.
24. Tanara G, Falugi C, Cesario A, Margaritora S, Russo P, Cosimi A. TP53 codon 72 polymorphism does not affect risk of cervical cancer in patients from The Gambia. Int J Biol Markers 2003;18:280-3.
25. Klug SJ, Ressing M, Koenig J, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol 2009;10:772-84.
26. Klug SJ, Wilmotte R, Santos C, et al. TP53 polymorphism, HPV infection, and risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 2001;10:1009-12.
27. Makni H, Franco EL, Kaiano J, et al. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 2000;87:528-33.
28. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007;26:1317-23.
29. Meissner Rde V, Barbosa RN, Fernandes JV, Galvao TM, Galvao AF, Oliveira GH. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil. Cancer Detect Prev 2007;31:371-4.
30. Niwa Y, Hirose K, Nakanishi T, et al. Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecol Oncol 2005;96:423-9.
31. Begleiter A, Norman A, Leitao D, et al. Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck. Oral Oncol 2005;41:927-33.